ClinicalTrials.gg
CompletedNCT04128007Updated Oct 26, 2022Results posted

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

A Phase 2 interventional study of Roflumilast foam 0.3% and Vehicle foam in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 47 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Psoriasis · Arcutis Biotherapeutics, Inc..

Enrollment
7th of 12
304 · median 318
Started
2020
with 3 others
Phase 2
5 of 12
none open now
Registered
4th of 12
by date

Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 7th largest by enrollment, is one of 4 that started in 2020, is one of 5 in phase 2, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. as a file.
02

Study summary

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Read the detailed description

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to adolescent and adult subjects with scalp and body psoriasis

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants legally competent to read, write, sign and give , or, in the case of adolscents, assent with consent of a parent(s) or legal guardian, as required by local laws.
  • Males and females ages 12 years and older (inclusive) at the time of consent for assent (for adolescents).
  • Scalp psoriasis with an Investigator Global Assessment of Scalp disease severity (S-IGA) of at least Mild ('2') at Baseline.
  • A Psoriasis Scalp Severity Index (PSSI) score of at least 6 at Baseline.
  • A PASI score of at least 2 (excluding the palms and soles) at Baseline.
  • Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator. Stable disease for the past 4 weeks.
  • Females of (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).
  • Females of non-childbearing potential must either be with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
  • Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.
  • Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.

Exclusion criteria

Exclusion Criteria:

  • Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments.
  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
  • Subjects currently taking lithium or antimalarial drugs.
  • Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).
  • Current diagnosis of non-plaque forms of psoriasis (e.g., guttate, erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.
  • Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
  • Known allergies to in ARQ-154.
  • Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study.
  • Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, , barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study.
  • Subjects with PHQ-8 >/= 10 or modified PHQ-A >/= 10 at Screening or Baseline.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of the product.
  • Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.
  • Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
  • Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
  • Subjects with active infection that required oral or intravenous administration of antibiotics, antifungal, or antiviral agents within 7 days of Baseline/Day 0.
  • Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    ARQ-154 foam 0.3%

    active

    Drug: Roflumilast foam 0.3%

  • Placebo comparator
    ARQ foam VehicleRQ-154 foam Vehicle

    placebo

    Drug: Vehicle foam

Interventions

  • experimental

    Also known as: ARQ-154

  • DrugVehicle foam

    experimental

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale

    The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.

    Time frame: Week 8

Secondary outcomes

  1. Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8

    The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.

    Time frame: Week 8

  2. Number of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score

    The number of participants with a baseline SI-NRS score ≥4 who achieve success (a ≥4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only.

    Time frame: Baseline and Weeks 2, 4, 8

  3. Change From Baseline in Psoriasis Symptoms Diary (PSD) Score

    The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity.

    Time frame: Baseline and Weeks 4 and 8

  4. Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score

    The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only.

    Time frame: Up to 8 weeks

  5. Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)

    The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.

    Time frame: Week 8

  6. Number of Participants Achieving PSSI-90

    The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.

    Time frame: Baseline and Week 8

07

Results

Posted Sep 30, 2022

Participant flow

Participant flow — Overall Study
MilestoneRoflumilast Foam 0.3%Vehicle Foam
Started200104
Completed17787
Not completed2317
Withdrew: Withdrawal by subject96
Withdrew: Protocol violation10
Withdrew: Lost to follow-up87
Withdrew: Adverse event52
Withdrew: Not reported02

Outcome measures

PrimaryNumber of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale

The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale10710
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 14.65 · 95% CI 6.64 to 32.32Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8

The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8736
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 8.80 · 95% CI 3.65 to 21.18Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score

The number of participants with a baseline SI-NRS score ≥4 who achieve success (a ≥4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only.

Time frame:
Baseline and Weeks 2, 4, 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Week 27414
Week 49819
Week 811015
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.06 · 95% CI 2.14 to 7.71Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.) · Odds ratio (or): 5.36 · 95% CI 2.93 to 9.78Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.) · Odds ratio (or): 9.74 · 95% CI 5.02 to 18.89Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.
SecondaryChange From Baseline in Psoriasis Symptoms Diary (PSD) Score

The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity.

Time frame:
Baseline and Weeks 4 and 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Psoriasis Symptoms Diary (PSD) Score
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Week 4-45.0 (-53.8 to -36.1)-25.4 (-35.2 to -15.6)
Week 8-55.0 (-64.0 to -46.1)-27.5 (-37.5 to -17.6)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = <0.0001 · Least squares mean difference: -19.6 · 95% CI -27.4 to -11.8ANCOVA with country; treatment; and baseline S-IGA, B-IGA, and PSD scores as independent variables with multiple imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = <0.0001 · Least squares mean difference: -27.5 · 95% CI -35.5 to -19.5ANCOVA with country; treatment; and baseline S-IGA, B-IGA, and PSD scores as independent variables with multiple imputation of missing data.
SecondaryTime to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score

The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only.

Time frame:
Up to 8 weeks
Reported as:
Median · days
Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score
daysRoflumilast Foam 0.3%Vehicle Foam
Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score28.0 (17.0 to 29.0)NA (67 to NA)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Log Rank · p = <0.0001 (Stratified by country, baseline S-IGA, and baseline B-IGA per randomization.) · Hazard ratio (hr): 3.940 · 95% CI 2.764 to 5.616Stratified by country, baseline S-IGA, and baseline B-IGA per randomization.
SecondaryNumber of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)

The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)12119
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.) · Odds ratio (or): 9.46 · 95% CI 4.81 to 18.61Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving PSSI-90

The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.

Time frame:
Baseline and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving PSSI-90
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Number of Participants Achieving PSSI-90843
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 34.45 · 95% CI 8.49 to 139.77Stratified by country, baseline S-IGA, and baseline B-IGA per randomization with multiple imputation of missing data.

Adverse events

Collected over Up to 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Foam 0.3%0/198 (0%)1/198 (0.5%)0/198 (0%)
Vehicle Foam0/104 (0%)0/104 (0%)0/104 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Foam 0.3%Vehicle Foam
Testicular torsionReproductive system and breast disorders1/1980/104

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Foam 0.3%Vehicle FoamTotal
Mean45.2 ± 14.2245.0 ± 15.7645.1 ± 14.74
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Female9647143
Male10457161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Hispanic or Latino382563
Not Hispanic or Latino16179240
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
American Indian or Alaska Native000
Asian7411
Native Hawaiian or Other Pacific Islander011
Black or African American9615
White18091271
More than one race112
Unknown or Not Reported314
Scalp Investigator Global Assessment (S-IGA) Baseline Score
Scalp Investigator Global Assessment (S-IGA) Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
0 - clear000
1 - almost clear000
2 - mild181432
3 - moderate15180231
4 - severe291039
Psoriasis Scalp Severity Index (PSSI) Baseline Score
Psoriasis Scalp Severity Index (PSSI) Baseline Score(score on a scale)Roflumilast Foam 0.3%Vehicle FoamTotal
Mean22.4 ± 12.5220.9 ± 11.7021.9 ± 12.25
Body Investigator Global Assessment (B-IGA) Baseline Score
Body Investigator Global Assessment (B-IGA) Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
0 - clear000
1 - almost clear000
2 - mild6939108
3 - moderate11960179
4 - severe10515
Scalp Itch Numeric Rating Scale (SI-NRS) Baseline Score
Scalp Itch Numeric Rating Scale (SI-NRS) Baseline Score(score on a scale)Roflumilast Foam 0.3%Vehicle FoamTotal
Mean6.4 ± 2.356.6 ± 2.256.5 ± 2.31

1 further baseline measures are reported on the registry.

08

Study locations

47 sites
  • Arcutis Biotherapeutics Clinical Site 71
    Rogers, Arkansas 72758, United States
  • Arcutis Biotherapeutics Clinical Site 72
    Fremont, California 94538, United States
  • Arcutis Biotherapeutics Clinical Site 85
    San Diego, California 92123, United States
  • Arcutis Biotherapeutics Clinical Site 21
    Cromwell, Connecticut 06416, United States
  • Arcutis Biotherapeutics Clinical Site 91
    Boynton Beach, Florida 33437, United States
  • Arcutis Biotherapeutics Clinical Site 20
    Coral Gables, Florida 33134, United States
  • Arcutis Biotherapeutics Clinical Site 88
    Miami, Florida 33144, United States
  • Arcutis Biotherapeutics Clinical Site 90
    Miami, Florida 33714, United States
  • Arcutis Biotherapeutics Clinical Site 83
    Sweetwater, Florida 33172, United States
  • Arcutis Biotherapeutics Clinical Site 99
    Rolling Meadows, Illinois 60008, United States
  • Arcutis Biotherapeutics Clinical Site 78
    Indianapolis, Indiana 46250, United States
  • Arcutis Biotherapeutics Clinical Site 95
    Plainfield, Indiana 46168, United States
  • Arcutis Biotherapeutics Clinical Site 77
    Louisville, Kentucky 40217, United States
  • Arcutis Biotherapeutics Clinical Site 79
    Covington, Louisiana 70433, United States
  • Arcutis Biotherapeutics Clinical Site 94
    Metairie, Louisiana 70006, United States
  • Arcutis Biotherapeutics Clinical Site 73
    Fridley, Minnesota 55432, United States
  • Arcutis Biotherapeutics Clinical Site 84
    Saint Joseph, Missouri 64506, United States
  • Arcutis Biotherapeutics Clinical Site 98
    Portsmouth, New Hampshire 03801, United States
  • Arcutis Biotherapeutics Clinical Site 87
    High Point, North Carolina 27262, United States
  • Arcutis Biotherapeutics Clinical Site 96
    Bexley, Ohio 43209, United States
  • Arcutis Biotherapeutics Clinical Site 82
    Portland, Oregon 97210, United States
  • Arcutis Biotherapeutics Clinical Site 80
    Broomall, Pennsylvania 19008, United States
  • Arcutis Biotherapeutics Clinical Site 97
    Murfreesboro, Tennessee 37130, United States
  • Arcutis Biotherapeutics Site 70
    Arlington, Texas 76011, United States
  • Arcutis Biotherapeutics Clinical Site 76
    Austin, Texas 78759, United States
  • Arcutis Biotherapeutics Clinical Site 86
    College Station, Texas 77845, United States
  • Arcutis Biotherapeutics Clinical Site 74
    Houston, Texas 77056, United States
  • Arcutis Biotherapeutics Clinical Site 89
    Pflugerville, Texas 78660, United States
  • Arcutis Biotherapeutics Clinical Site 93
    San Antonio, Texas 78213, United States
  • Arcutis Biotherapeutics Clinical Site 81
    Norfolk, Virginia 23502, United States
  • Arcutis Biotherapeutics Clinical Site 75
    Richmond, Virginia 23220, United States
  • Arcutis Biotherapeutics Clinical Site 51
    Kogarah, New South Wales 2217, Australia
  • Arcutis Biotherapeutics Clinical Site 52
    Westmead, New South Wales 2145, Australia
  • Arcutis Biotherapeutics Clinical Site 54
    Hectorville, South Australia 5073, Australia
  • Arcutis Biotherapeutics Clinical Site 50
    East Melbourne, Victoria 3002, Australia
  • Arcutis Biotherapeutics Clinical Site 11
    Pleven, 5800, Bulgaria
  • Arcutis Biotherapeutics Clinical Site 13
    Sevlievo, 5402, Bulgaria
  • Arcutis Biotherapeutics Clinical Site 14
    Sofia, 1592, Bulgaria
  • Arcutis Biotherapeutics Clinical Site 10
    Sofia, 1606, Bulgaria
  • Arcutis Biotherapeutics Clinical Site 12
    Stara Zagora, 6003, Bulgaria
  • Arcutis Biotherapeutics Clinical Site 64
    Calgary, Alberta T1Y0B4, Canada
  • Arcutis Biotherapeutics Clinical Site 61
    Barrie, Ontario L4M 7G1, Canada
  • Arcutis Biotherapeutics Clinical Site 60
    London, Ontario N6H5L5, Canada
  • Arcutis Biotherapeutics Clinical Site 62
    Peterborough, Ontario K9J 5K2, Canada
  • Arcutis Biotherapeutics Clinical Site 63
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Biotherapeutics Clinical Site 66
    Montréal, Quebec H2X 2V1, Canada
  • Arcutis Biotherapeutics Clinical Site 65
    Westmount, Quebec H3Z 2S6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Sep 2020, 8 months.

Results were first posted in Sep 2022, 2 years after primary completion. A results delay was requested in Jun 2021.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Oct 16, 2019
StartActual
Jan 13, 2020
Primary completionActual
Sep 23, 2020
CompletionActual
Sep 25, 2020
Results delay requested
Jun 18, 2021
Results first posted
Sep 30, 2022
Last update
Oct 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04128007
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Jan 13, 2020
Primary completion
Sep 23, 2020
Completion
Sep 25, 2020
Results posted
Sep 30, 2022
Last update
Oct 26, 2022

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARQ-154

Start the discussion